People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Healthtech, Other, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Teladoc Health, Inc. | — | Healthtech | Growth/Late | $1.1B | $22.1B | 2014 |
| Pulmonx Corp | — | Other | Series C | $143.8M | $1.1B | 2015 |
| Invuity, Inc. | — | Other Health Care | Series B | $105.7M | $507.3M | 2010 |
| Intersect ENT, Inc. | — | Other Health Care | Series B | $85.7M | $462.2M | 2010 |
| BVI Audley, Inc. | — | Other | Series B | $33.6M | $241.0M | 2016 |
| Voyage Medical Inc | — | Other Health Care | Series B | $21.0M | $8.3M | 2010 |
| Corventis Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
Dana G. Mead, Jr. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dana G. Mead, Jr. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dana Mead | 3 | 7 |
| Arman Pahlavan | 1 | 12 |
| Michael Goldberg | 1 | 11 |
| Annette Campbell-White | 1 | 11 |
| Michael Baker | 1 | 8 |
| Frederic H. Moll | 1 | 8 |
| John Reardon | 1 | 7 |
| Michael King | 1 | 6 |
| Steve Salmon | 1 | 6 |
| Chris Ehrlich | 1 | 6 |
| WILLIAM H. FRIST | 1 | 6 |
| John Schilling | 1 | 6 |
| Evan S. Melrose | 1 | 5 |
| THOMAS MCKINLEY | 1 | 5 |
| Martin Felsenthal | 1 | 5 |
| James Outland | 1 | 4 |
| Richard Boxer | 1 | 4 |
| Michael Wiley | 1 | 4 |
| Howard Palefsky | 1 | 4 |
| Kevin Williamson | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.